Stocktoria
KORU Medical Systems, Inc. KRMD
KORU Medical Systems, Inc. (KRMD) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $41.1M at a -6.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.89 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.418 |
| Retained earnings / assets | -1.135 |
| EBIT / assets | -0.105 |
| Equity / liabilities | 1.529 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| KRMD | KORU Medical Systems, Inc. | 4/9 | -0.06 | — | +22.2% |
| SSII | SS Innovations International, Inc. | 4/9 | -0.09 | — | +105.7% |
| IDXG | INTERPACE BIOSCIENCES, INC. | 4/9 | -16.52 | 1.9 | -17.5% |
| UTMD | UTAH MEDICAL PRODUCTS INC | 3/9 | — | — | -5.8% |
| SNWV | SANUWAVE Health, Inc. | 6/9 | -19.06 | 6.3 | +35% |
| TLSI | TriSalus Life Sciences, Inc. | 4/9 | — | — | +53.4% |
| CTSO | Cytosorbents Corp | 3/9 | — | — | +4.1% |
About KORU Medical Systems, Inc.
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 Syringe Driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.
FAQ
Is KRMD financially healthy?
KORU Medical Systems, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does KRMD pay a dividend?
No, KORU Medical Systems, Inc. does not currently pay a dividend.
How profitable is KRMD?
In FY2025, KORU Medical Systems, Inc. had a net margin of -6.4% and a return on equity of -15.5%.
Is KRMD overvalued or undervalued?
KORU Medical Systems, Inc. trades at about 330.0× trailing earnings — above its 10-year norm (10-year range 10.0×–594.0×, median 17.0×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for KRMD?
The average Wall-Street price target for KORU Medical Systems, Inc. is $6.80, about 106.1% above the recent price, from 5 analysts.
Is KRMD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on KORU Medical Systems, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.